Intellia Therapeutics, Inc.

Intellia Therapeutics is a clinical-stage biotechnology company developing gene-editing therapies using CRISPR/Cas9 technology. The preclinical development of such therapies, including Intellia's lead programs for transthyretin amyloidosis (ATTR) and hemophilia, inherently requires animal testing to evaluate safety, efficacy, and biodistribution before advancing to human trials. Regulatory authorities, including the U.S. Food and Drug Administration, mandate this animal data as part of the investigational new drug application process.

The company's SEC filings routinely reference preclinical animal studies as a core component of its research activities. For instance, its collaboration and license agreements contemplate the completion of these studies. As a biopharmaceutical company whose product candidates are novel biological entities, Intellia's operational model is fundamentally reliant on animal testing to fulfill regulatory requirements and advance its pipeline.